Income Tax Expense (Benefit) in USD of REGENERON PHARMACEUTICALS, INC. from Q1 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
REGENERON PHARMACEUTICALS, INC. quarterly/annual Income Tax Expense (Benefit) history and change rate from Q1 2010 to Q3 2025.
  • REGENERON PHARMACEUTICALS, INC. Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was $303M, a 99% increase year-over-year.
  • REGENERON PHARMACEUTICALS, INC. Income Tax Expense (Benefit) for the twelve months ending 30 Sep 2025 was $567M, a 80.1% increase year-over-year.
  • REGENERON PHARMACEUTICALS, INC. annual Income Tax Expense (Benefit) for 2024 was $367M, a 49.5% increase from 2023.
  • REGENERON PHARMACEUTICALS, INC. annual Income Tax Expense (Benefit) for 2023 was $246M, a 52.8% decline from 2022.
  • REGENERON PHARMACEUTICALS, INC. annual Income Tax Expense (Benefit) for 2022 was $520M, a 58.4% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

REGENERON PHARMACEUTICALS, INC. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $567M $303M +$151M +99% 01 Jul 2025 30 Sep 2025 10-Q 28 Oct 2025
Q2 2025 $416M $127M -$68.7M -35.1% 01 Apr 2025 30 Jun 2025 10-Q 01 Aug 2025
Q1 2025 $485M $96.3M +$118M 01 Jan 2025 31 Mar 2025 10-Q 29 Apr 2025
Q4 2024 $367M $40.4M +$52.4M 01 Oct 2024 31 Dec 2024 10-K 05 Feb 2025
Q3 2024 $315M $152M +$49.4M +48% 01 Jul 2024 30 Sep 2024 10-Q 28 Oct 2025
Q2 2024 $266M $196M +$81.3M +71% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2025
Q1 2024 $184M -$21.3M -$61.5M -153% 01 Jan 2024 31 Mar 2024 10-Q 29 Apr 2025
Q4 2023 $246M -$12M -$140M -109% 01 Oct 2023 31 Dec 2023 10-K 05 Feb 2025
Q3 2023 $385M $103M -$91.1M -46.9% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024
Q2 2023 $476M $115M +$3.4M +3.06% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024
Q1 2023 $473M $40.2M -$47.4M -54.1% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024
Q4 2022 $520M $128M -$147M -53.5% 01 Oct 2022 31 Dec 2022 10-K 05 Feb 2025
Q3 2022 $667M $194M +$9.7M +5.26% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023
Q2 2022 $658M $111M -$543M -83% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023
Q1 2022 $1.2B $87.6M -$50.2M -36.4% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023
Q4 2021 $1.25B $274M +$199M +264% 01 Oct 2021 31 Dec 2021 10-K 05 Feb 2024
Q3 2021 $1.05B $184M +$28.2M +18.1% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 $1.02B $654M +$632M +2927% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022
Q1 2021 $391M $138M +$93.8M +213% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022
Q4 2020 $297M $75.4M -$22.4M -22.9% 01 Oct 2020 31 Dec 2020 10-K 06 Feb 2023
Q3 2020 $320M $156M +$57.3M +57.9% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 $262M $21.6M -$10M -31.6% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $272M $44M -$41M -48.2% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 $313M $97.8M +$242M 01 Oct 2019 31 Dec 2019 10-K 07 Feb 2022
Q3 2019 $71.3M $98.9M +$57.7M +140% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 $13.6M $31.6M -$73.1M -69.8% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020
Q1 2019 $86.7M $85M -$22.4M -20.9% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020
Q4 2018 $109M -$144M -$525M -138% 01 Oct 2018 31 Dec 2018 10-K 08 Feb 2021
Q3 2018 $635M $41.2M -$136M -76.8% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019
Q2 2018 $771M $105M -$33.4M -24.2% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019
Q1 2018 $804M $107M -$76M -41.4% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019
Q4 2017 $880M $381M +$293M +331% 01 Oct 2017 31 Dec 2017 10-K 07 Feb 2020
Q3 2017 $587M $177M +$76.2M +75.4% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018
Q2 2017 $511M $138M +$42.1M +43.8% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018
Q1 2017 $469M $183M +$34.6M +23.3% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2018
Q4 2016 $434M $88.4M +$16.1M +22.3% 01 Oct 2016 31 Dec 2016 10-K 07 Feb 2019
Q3 2016 $418M $101M -$81.8M -44.7% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017
Q2 2016 $500M $96M -$37.3M -28% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017
Q1 2016 $537M $149M -$51.7M -25.8% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017
Q4 2015 $589M $72.3M -$27.3M -27.4% 01 Oct 2015 31 Dec 2015 10-K 08 Feb 2018
Q3 2015 $616M $183M +$84.4M +85.8% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016
Q2 2015 $532M $133M +$20.9M +18.6% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016
Q1 2015 $511M $201M +$87.9M +78.1% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016
Q4 2014 $423M $99.6M +$4.64M +4.88% 01 Oct 2014 31 Dec 2014 10-Q 04 Nov 2015
Q3 2014 $418M $98.4M +$14.1M +16.7% 01 Jul 2014 30 Sep 2014 10-Q 04 Nov 2015
Q2 2014 $404M $112M +$52.1M +86.4% 01 Apr 2014 30 Jun 2014 10-Q 04 Aug 2015
Q1 2014 $352M $113M +$69.6M +162% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015
Q4 2013 $283M $95M +$431M 01 Oct 2013 31 Dec 2013 10-K 11 Feb 2016
Q3 2013 -$148M $84.4M 01 Jul 2013 30 Sep 2013 10-Q 04 Nov 2014
Q2 2013 $60.3M +$60.3M 01 Apr 2013 30 Jun 2013 10-Q 05 Aug 2014
Q1 2013 $43M 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014
Q4 2012 -$336M -$335M -54502% 01 Oct 2012 31 Dec 2012 10-K 13 Feb 2014
Q2 2012 $0 +$863K 01 Apr 2012 30 Jun 2012 10-Q 25 Jul 2012
Q4 2011 -$1.13M -$615K -$615K 01 Oct 2011 31 Dec 2011 10-K 13 Feb 2014
Q3 2011 -$517K $562K +$562K 01 Jul 2011 30 Sep 2011 10-Q 24 Oct 2012
Q2 2011 -$1.08M -$863K -$863K 01 Apr 2011 30 Jun 2011 10-Q 25 Jul 2012
Q1 2011 -$216K -$216K* -$216K 01 Jan 2011 31 Mar 2011 10-Q 26 Apr 2012
Q4 2010 $0 $0 01 Oct 2010 31 Dec 2010 10-K 21 Feb 2012
Q3 2010 $0 01 Jul 2010 30 Sep 2010 10-Q 27 Oct 2011
Q2 2010 $0 01 Apr 2010 30 Jun 2010 10-Q 28 Jul 2011
Q1 2010 $0 01 Jan 2010 31 Mar 2010 10-Q 03 May 2011

REGENERON PHARMACEUTICALS, INC. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $367M +$122M +49.5% 01 Jan 2024 31 Dec 2024 10-K 05 Feb 2025
2023 $246M -$275M -52.8% 01 Jan 2023 31 Dec 2023 10-K 05 Feb 2025
2022 $520M -$730M -58.4% 01 Jan 2022 31 Dec 2022 10-K 05 Feb 2025
2021 $1.25B +$953M +321% 01 Jan 2021 31 Dec 2021 10-K 05 Feb 2024
2020 $297M -$16.1M -5.14% 01 Jan 2020 31 Dec 2020 10-K 06 Feb 2023
2019 $313M +$204M +187% 01 Jan 2019 31 Dec 2019 10-K 07 Feb 2022
2018 $109M -$771M -87.6% 01 Jan 2018 31 Dec 2018 10-K 08 Feb 2021
2017 $880M +$446M +103% 01 Jan 2017 31 Dec 2017 10-K 07 Feb 2020
2016 $434M -$155M -26.3% 01 Jan 2016 31 Dec 2016 10-K 07 Feb 2019
2015 $589M +$166M +39.2% 01 Jan 2015 31 Dec 2015 10-K 08 Feb 2018
2014 $423M +$140M +49.7% 01 Jan 2014 31 Dec 2014 10-K 09 Feb 2017
2013 $283M +$618M 01 Jan 2013 31 Dec 2013 10-K 11 Feb 2016
2012 -$336M -$335M -29569% 01 Jan 2012 31 Dec 2012 10-K 12 Feb 2015
2011 -$1.13M -$1.13M 01 Jan 2011 31 Dec 2011 10-K 13 Feb 2014
2010 $0 01 Jan 2010 31 Dec 2010 10-K 21 Feb 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.